Trans Asia Peer Comparison

BSE: 530783

₹3.20

₹-0.16 (-4.76%)

As on 19-Oct-2021IST

Market cap

₹2 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

4

Div. Yield

0 %

Edit

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	2	36,827	27,985	27,762	26,788
Revenue (₹ Cr)	--	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	-5.59	414.00	-371.81	288.22	387.35
Net Margin (%)	-46,583.33	11.23	-3.93	14.79	26.01
RoE (%)	-4.30	8.38	-3.85	29.77	25.18
Price to Earnings	--	90.04	--	96.32	69.36
Price-To-Book	3.98	7.32	3.50	20.68	15.53

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	0.00	2,843.99	--	263.02	239.64
Total Income	0.00	2,904.07	--	281.09	242.49
Total Expenditure	0.08	2,746.23	--	182.42	198.63
EBITDA	-0.08	97.76	--	80.60	41.02
Depreciation	--	224.14	--	18.45	3.52
EBIT	-0.08	-126.38	--	62.15	37.50
Interest	0.00	275.74	--	6.20	5.59
Other Income	--	60.08	--	18.07	2.84
Exceptional Items	-1.17	--	--	--	--
Profit before Tax	-0.08	-342.04	--	74.01	34.75
Provision for Tax	0.08	-204.09	--	24.60	7.28
Profit after Tax	-0.08	-137.95	--	49.41	27.47

Liabilities (₹ Cr)

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	6.01	2,671.67	--	340.50	111.81
Minority Interest	--	385.79	--	--	--
Non-Current Liabilities	0.01	1,194.85	--	9.30	25.46
Current Liabilities	0.74	3,497.18	--	77.54	94.61
Total Liabilities	6.76	8,147.66	--	430.39	231.89

Assets (₹ Cr)

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	4.90	5,319.66	--	162.50	104.93
Current Assets	1.86	2,400.54	--	264.84	121.04
Total Assets	6.76	8,147.66	--	430.39	231.89
Total Debt*	0.15	3,213.23	--	30.27	59.42
Net Current Assets	1.12	-1,096.64	--	187.31	26.42
Contingent Liabilities	--	641.08	--	46.45	0.07

Cashflow (₹ Cr)

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	0.66	648.96	--	5.47	27.08
Cash Flow from Investing Activities	-0.66	-155.53	--	-84.34	-23.94
Cash from Financing Activities	--	-679.58	--	80.07	0.19
Net Cash Inflow / Outflow	0.00	-186.15	--	1.21	3.33

Ratios

Profitability Ratios

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	-1.33	-1.11	--	26.00	27.09
ROE (%)	-1.36	-5.22	--	18.67	29.78
ROA (%)	-1.22	-1.80	--	13.65	12.34
EBIT Margin (%)	--	5.55	--	37.51	18.30
Net Margin (%)	--	-4.75	--	17.58	11.33
Cash Profit Margin (%)	--	3.03	--	25.80	12.93

Growth Ratios

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	--	-20.24	--	71.02	0.47
EBIT Growth (%)	-23.86	1,004.01	--	159.60	3.29
Net Profit Growth (%)	93.73	55.76	--	168.16	17.92
EPS Growth (%)	93.73	64.44	--	148.52	17.92
Book Value Growth (%)	-1.35	-0.03	--	68.83	34.77

Valuation Ratios

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	0.00	0.00	--	0.00	0.00
Price / Book Value	0.30	0.72	--	0.00	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-23.67	30.78	--	0.00	1.51
Market Cap (₹ Cr)	--	1,913.03	--	0.00	0.00

Solvency Ratios

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.03	1.22	--	0.09	0.56
Short term debt to equity ratio	0.02	0.34	--	0.06	0.30
Current Ratio	2.51	0.69	--	3.42	1.28
Quick Ratio	2.51	0.48	--	2.93	0.73
Interest Coverage	-67.10	-0.24	--	12.93	7.22

Operating Efficiency Ratios

	Trans Asia	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	--	43.70	--	53.26	23.54
Asset Turnover	0.00	0.37	--	0.73	1.08
Receivable days	--	161.49	--	155.79	100.90
Inventory Days	--	98.54	--	39.61	69.31
Payable days	--	263.19	--	159.03	169.65
Cash Conversion Cycle	--	-3.16	--	36.37	0.56

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.